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Abstract: Gender and sex hormones can influence a variety of mental health states, including 
mood, cognitive development and function, and vulnerability to neurodegenerative diseases 
and brain damage. Functions of neuronal cells may be altered by estrogens depending upon 
the availability of different physiological estrogenic ligands; these ligands and their effects 
vary with life stages, the genetic or postgenetic regulation of receptor levels in specific tissues, 
or the intercession of competing nonphysiological ligands (either intentional or unintentional, 
beneficial to health or not). Here we review evidence for how different estrogens (physiological 
and environmental/dietary), acting via different estrogen receptor subtypes residing in   alternative 
subcellular locations, influence brain functions and behavior. We also discuss the families of 
receptors and transporters for monoamine neurotransmitters and how they may interact with 
the estrogenic signaling pathways.
Keywords: estrogen receptor α, estrogen receptor β, GPR30, GPER, xenoestrogens, phytoe-
strogens, transporters, brain function, neurotransmitter receptors
Estrogens, or the immediate downstream products that they induce, have long been 
known to alter reproductive behaviors. Prime examples are sexual receptivity and 
maternal behavior.1,2 However, estrogens can also modify   nonreproductive behaviors 
and cellular responses including mood, affect, anxiety, fear, locomotor activity,3–5 tumor 
susceptibility,6 and vulnerability to addictive drugs.7 In some cases these estrogenic 
influences on behavior have been localized to specific brain areas. For example, estro-
gens alter locomotor activity via actions in the medial preoptic area,8 while anxiety 
and conditioned fear appear to be controlled by the amygdala,9 and   developmental and 
tumor growth effects have been documented in the   cerebellum.10 Each of these brain 
regions expresses both α and β subtypes of estrogen receptors (ERs),11 although their 
balance varies between locations. Other, more novel ER   candidates found in multiple 
brain areas12–14 are also beginning to be examined.
Life stage-specific, fluctuating levels of several 
physiological estrogens, and their relationship  
to diseases and vulnerabilities in women
There are major sex-based differences in diseases in which neurotransmitters, and their 
transporters and receptors, play a role. For example, depression is more prevalent in 
women,15 especially during periods of fluctuating estrogen levels.16,17 Diseases involv-
ing the dopamine transporter (DAT) such as Parkinson’s, Alzheimer’s, Tourette’s, and 
attention-deficit hyperactivity disorder (ADHD), worsen in women after menopause,18 International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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or are different in premenopausal versus postmenopausal 
females,19–25 suggesting a protective effect of estrogens, or 
altered vulnerabilities. Receptors and   transporters for other 
catecholamines [notably the serotonin transporter (SERT) and 
the norepinephrine transporter (NET)] may also be involved 
in these sex-biased diseases.26–28
Because estrogen actions can alter the function of these 
machineries for neurotransmission, it is important to review 
the fluctuations in hormone levels that affect women. 
Levels of the most prominent physiological estrogens rise 
  dramatically during pregnancy (see Figure 1), and return to 
prepregnancy levels very rapidly after parturition; this abrupt 
change can be correlated with the onset of postpartum depres-
sion.29 Levels of these hormones also vary widely between 
the sexes, and between women’s cycle stages and life stages 
(Figure 2). These changes are a likely basis for age- or preg-
nancy status-specific disease biases in women.30–32 Ovarian 
hormones fluctuate in perimenopause, followed eventually 
by chronically lower levels33 that can be correlated with the 
onset of mood disorders and reward circuit-based or other 
behavioral disturbances. Likewise, pubertal and menstrual 
cycle-based fluctuations can also lead to phase-dependent 
mood disorders.34–40 Females are more vulnerable to cocaine 
use disorders than males,4,7,41,42 and depressive states associ-
ated with drug addiction vulnerability or lack of recovery 
success can coincide with the rise and decline of estrogens.43 
Crises in schizophrenia/bipolar disorders can sometimes 
be directly correlated to menstrual cycle-related hormonal 
fluctuations.17,44 Estradiol (E2) can rapidly reverse the effects 
of selective serotonin reuptake inhibitors (SSRIs) used to treat 
depression.45 Estrogens may also be involved in cognitive 
function and attention.46,47 These observations suggest that 
dramatic fluctuations in estrogens or their downstream effec-
tors are key to our understanding of these life stage-specific 
disease biases in women.
Is there evidence that treatment with estrogens can 
  alleviate some of these conditions and diseases caused by 
deficits or dramatic decreases in estrogens? Although it has 
been proposed that a more rapid decline in E2 is associated 
with postpartum depression, some recent evidence does not 
fully support this notion.48 However, treatment with estrogens 
can relieve some cases of postpartum   depression,31,49–51 and 
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Figure 1 Hormone level changes in predominant physiological estrogens in the nonpregnant state versus the trimesters of pregnancy. 
Note: The levels of the estrogens estrone, estradiol, and estriol (e1, e2, and e3, respectively) drop rapidly to nonpregnant levels at parturition. Graphed from published data 
tables.226International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
155
estrogens and mental health
some experimental designs that simulate pre- and postpartum 
estrogen levels also   support this conclusion.52 Yet E2 therapy 
in humans can be   ineffective in reversing mood depression 
or other purportedly   estrogen-influenced diseases.50,52–56 One 
explanation for these discrepancies could be the involvement 
of other prominent estrogen metabolites [eg, estrone (E1) and 
estriol (E3); see Figures 1 and 2] that have not been studied 
nearly as   extensively for these activities. They can have 
potent nongenomic actions,57,58 in contrast to their previously 
determined minor role in genomic responses as “weak” estro-
gens. A few studies have looked at the effects of E1 or E3 on 
behavior,59–61 but most have focused on treatments with E2, 
with substrates for several estrogens (DHEA), or mixtures of 
estrogens such as Premarin®, making it difficult to interpret 
effects of individual estrogens in those preparations.
The primary physiological estrogens (E1, E2, and E3) are 
predominantly synthesized in the ovaries, though they can also 
be synthesized in placenta (especially E3),62 brain,63,64 and fat 
cells.65 The levels of these hormones are therefore affected by 
the quantity and state of such non ovarian tissues. In addition, 
reports that only large doses of estrogens can improve mood 
disorders66 may suggest the involvement of metabolites of the 
administered compound (usually E2); these would be present 
in smaller amounts and could only accumulate to active levels 
after a large dose of the precursor estrogen is given. 
Effects mediated by peptide 
hormones downstream of estrogens
Besides direct actions of estrogens on behavior, there are 
also indirect effects that cause synthesis of other receptors,67 
or synthesis and secretion of peptide hormones which act 
downstream. A classic example of such indirect action is 
production and secretion of the hormone prolactin (PRL). 
In the pituitary, estrogens facilitate both synthesis and regu-
lated secretion of PRL.68 PRL and its receptors are widely 
distributed throughout the body. Most actions elicited by 
this hormone are directly or indirectly related to reproductive 
processes (such as lactation). However, behavioral changes 
that facilitate reproductive success also result. Behavioral 
hallmarks associated with high PRL levels are diverse, and 
can be elicited in both pregnancy and pseudopregnancy 
(when PRL levels rise without a pregnancy). These include 
maternal behavior (including aggressiveness associated with 
protectiveness and territoriality) and sexual dysfunction 
(which may prevent a subsequent pregnancy during a critical 
infant developmental period). PRL overstimulation can also 
be correlated with depression, changed affect, and abnormal 
responses to stress.69 As dopamine of hypothalamic origin pro-
vides D2 dopamine receptor-mediated inhibitory control over 
PRL secretion,70 and PRL and/or estrogens may also affect 
dopamine71 and serotonin signaling,72 there is clear interplay 
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Figure  2  Hormone  level  changes  in  predominant  physiological  estrogens  with  increasing  age  in  females  compared  to  males,  and  during  menstrual  cycle  phases.   
Note: These levels are depicted on scales three orders of magnitude lower than those used in Figure 1. The levels of the estrogens estrone, estradiol, and estriol (e1, e2, 
and e3, respectively) are shown for females (♀) and males (♂). The cycle phases depicted are early follicular (eF), pre-ovulatory (PO), midcyle peak (MP), luteal (L), and 
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among these factors. Low dopamine levels (associated with 
depression) also relieve dopamine’s suppressive effect on PRL 
secretion in the pituitary, thus perhaps compounding adverse 
effects on mood. Estrogen-induced cell proliferation is also 
part of the normal response of the pituitary and many other 
reproduction-related tissues.73,74 Estrogen exposures at the 
wrong levels or of inappropriate types can cause disregulated 
proliferation, and even produce tumors of those tissues,75–77 
including the pituitary;78 behavioral issues are compounded 
if these tumors are prolactinomas.
Models for cellular mechanisms  
of estrogen action
The vast majority of studies on the mechanisms of estrogen 
(and other steroid) actions over the past 40–50 years focused 
on nuclear transcription (genomic) effects.79–81 However, 
more recent evidence (including our own)82–89 also supports 
nongenomic steroid actions initiated at the level of the 
cell membrane.90–93 While we are beginning to understand 
the various ways in which E2 acts via membrane receptor- 
initiated pathways, we still know very little about nongenomic 
responses to other prominent physiological estrogens (such as 
E1 and E3) or xenoestrogens (see below), and still less about 
other metabolites of these compounds. Membrane-initiated 
signaling pathways include complex webs of interacting 
signals that can converge to ramp a particular function 
up or down, and can have either immediate mechanistic 
consequences due to rapid signaling, or later downstream 
consequences after the accumulation of signaling cascade 
intermediates, or phosphorylation of transcription factors.94 
Multiple individual pathways must thus be tested to compre-
hensively understand functional control via such regulatory 
mechanisms, and their effects on women’s health.
Which receptors mediate  
these responses?
Many areas of the brain express both ERα and ERβ,95 
although the receptors and their functions can vary during 
different stages of development. Various approaches have 
been used to detect selective actions of these subtypes96 
the most recent and convincing of which are ERα versus 
ERβ-selective ligands (PPT versus DPN, respectively) or 
knockdowns/knockouts of the ERs. DPN selectively regulates 
AMPA receptor subunits GluR2/3 in the hipopocampus97 
and also opposes ERα induction of   progesterone receptors 
in the ventromedial nucleus.98 ERβ can modulate DATs and 
D2 receptors in rats.99 ERα is thought to participate in striatal 
dopamine neuroprotection.100 However, the neuroprotective 
effects of estrogens are usually seen at much higher than 
physiological concentrations, and therefore may also act via 
nonreceptor-mediated mechanisms, such as changing fluidity 
of membranes surrounding the receptors, in which steroids 
dissolve readily at these high concentrations. Few studies 
have as yet been aimed at examining α- versus β-selective 
behavior; though some have been inconclusive,101 others 
have shown ERβ-specific effects on object recognition and 
placement tasks.102
In our own studies we examined nongenomic effects of 
estrogens on the stimulation of dopamine efflux in PC12 
cells;103 we showed that plasma membrane versions of ERs 
(mERα and mERβ) and the newly renamed GPER (formerly 
called GPR30) are all involved in nongenomic estrogenic 
effects.85–89,104,105 GPER is a membrane ER of a different 
receptor family106–108 that works by activating matrix metal-
loproteinase that in turn cleaves active epidermal growth 
factor (EGF) from a tethered heparin-bound EGF mem-
brane protein precursor, triggering subsequent action via 
the EGF receptor. A family of GPER-related receptors was 
identified in a wide variety of tissues and species, including 
humans; multiple reports indicate that GPER is present in 
the brain,12–14,109 though knowledge of its behavioral effects is 
still pending. We determined that GPER RNA and protein are 
expressed in PC12 cells,58,103,110 where a recently developed 
GPER-selective ligand111 appears to have inhibitory effects 
on ERα-stimulated dopamine efflux via the DAT, similar to 
GPER’s inhibitory effects in other tissues.109,112
Signaling from both the cell surface 
and from the nucleus – fitting 
estrogenic actions into the big 
picture
Ligands first encountered at a cell’s surface generally initiate 
cellular responses to a changing environment. Other classes 
of plasma membrane receptors have long been associated 
with membrane-initiated rapid signaling cascades; ERs 
that employ these signaling mechanisms are relatively new 
  considerations. Such events can set into motion coordinated 
actions   eventually leading to one of three main cell fates: pro-
liferation,   differentiation, or death. To direct the cell toward 
one of these decisions, multiple signaling pathways must 
funnel into a final common pathway signal, such as those 
involving mitogen-activated protein kinases (MAPKs). These 
enzymatic “signal receiving stations” sum many inputs from 
multiple signaling cascades to result in a tally of active MAPKs 
(with ERKs, JNKs, and p38 subtypes). Thus many stimuli can International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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reconcile to a final decision for a major cellular response. Act-
ing via their membrane receptors, steroids are only one class 
of input signals to the MAPK “signal   integrator”. Estrogenic 
signals combine with those from other pathways, originating 
either from the cell surface or from intracellular locations.
The integration of these signal inputs is complex. Not all 
estrogens elicit identical responses (in level or timing) along 
these pathways.82 Also, as each tissue may contain a different 
repertoire of signaling machineries, the complex mixture of pat-
terns leading to pivotal cellular fate decisions will likely also be 
tissue-specific. Fluctuating endogenous metabolites, along with 
introduced pharmaceutical estrogens or other nonphysiological 
estrogen mimetics (see below) can all contribute to a different 
final tally with distinct kinetics, and so lead to alternative final 
cellular responses. Therefore, discovering the spectrum of 
responses within the complex signaling web particular to each 
part of the brain will be an important goal for understanding the 
impact of estrogens on women’s behavioral health.
The cell biology and biochemistry 
of transporter function, and their 
regulation by estrogens
Many drugs currently used to treat behavioral disorders 
target the DAT and/or the SERT.113,114 Transporters of this 
family are recognized as the predominant mechanism for 
  maintaining   adequate synaptic levels of the corresponding 
  neurotransmitters. For instance, in DAT or SERT knockout mice 
the synthetic machinery for producing new   neurotransmitters 
cannot compensate for the loss of neurotransmitter reuptake 
via these transporters.115   Transporters in this family (DAT, 
SERT, and NET) all have 12 transmembrane regions, with 
both the N- and C-termini located within the cytoplasm, and a 
  proposed structure-based mechanism for opening and closing 
extracellular versus cytoplasmic substrate (neurotransmitter) 
gates.116–118 Various therapeutic drugs and the addictive drugs 
cocaine, methamphetamine, and amphetamine bind to the 
DAT and inhibit or reverse its activity119–121 via mechanisms 
now beginning to be understood at the cellular and molecular 
levels. Some evidence also suggests that agents that cause DAT 
and SERT phosphorylation may regulate their removal from 
the plasma membrane and sequestration to an intracellular 
compartment.122–126 Protein kinases PKC and PKG and the 
p38 MAPK127 probably128 mediate these effects by modifying 
a C-terminal pentapeptide sequence that is homologous across 
the DAT, SERT, and NET proteins.
It is also possible that many different kinases controlled by 
estrogens regulate neurotransmitter transporters. We recently 
determined that E2 can rapidly alter several signaling pathways 
in PC12 cells to cause efflux of dopamine via the DAT;58 PKC 
and MEK (the enzyme upstream of the MAPK-ERKs) are acti-
vated by E2. E2 also increases intracellular calcium levels via 
release from stores. In addition, from our work in the pituitary 
field, and the work of others, we know that multiple estrogens 
induce activation of MAPKs.129,130 The estrogenic activation of 
other kinases likely to act on DAT’s N-terminal tail have yet 
to be investigated;93,131 these include PKA, PKG, the subtypes 
of PKC (α, βI, and II, γ), calmodulin kinase II (CamKII)132,133 
and Cdk5.134 Such modifiers of phosphorylation and activity 
states could affect DAT in a variety of ways, including revers-
ing the   direction of transport,120,121,135,136 and/or degradation 
or removal of the transporter from the membrane.115,123,125,137 
Specific   phosphatases are also now being investigated for their 
role in maintaining a balance of phosphorylation at specific 
serines, threonines, and tyrosines at the cytosolic accessible 
regulatory tails of transporters;133 the part played by estrogens 
in these processes is largely unknown.
Both neurotransmitter transporters and receptors can be 
found in the same specialized membrane   compartment as 
ERs – the cholesterol-rich microdomains or caveolae.138–140 
Many kinases and phosphatases also reside here.132,138,140,141 
However, nonraft or caveolar plasma membrane   populations 
of these groups of proteins also exist, and the regulated 
movement between compartments is not yet under-
stood.   ER-induced kinase and phosphatase effects on 
  neurotransporters and neurotransmitter receptors could be 
either direct or indirect (via intervening enzymes in signaling 
cascades), so mERs may or may not need to interact directly 
with these parts of the neurotransmission machinery in the 
same membrane compartment.
There are also sex differences in the expression levels and 
localization of DAT; females express higher DAT levels in the 
striatum than men,142 although men experience higher amplifi-
cation of amphetamine-stimulated striatal dopamine release,143 
perhaps because of their lower baseline levels due to lower 
endogenous estrogen levels. Sex steroid levels in females also 
correlate with different behavioral/  neurochemical responses 
to drugs.144 The euphoric effects of psychoactive drugs are 
greatest during the follicular phase of the menstrual cycle, 
when the highest E2 levels occur (see Figure 2).145
New parallels between the actions of estrogens and drugs 
of abuse on the DAT have recently been identified. Both 
amphetamines118,146,147 and estrogens58,103,148 can induce reversal 
of the DAT to cause dopamine efflux. Other coincident actions 
include DAT trafficking caused by amphetamines and some 
estrogens (though sometimes in different directions),149,150 and 
the dependence of efflux caused by both compounds on PKC International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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actions and release of intracellular calcium stores.   However, out-
comes can depend upon whether transporter expression is under 
the control of endogenous or transfection-driven   expression.128 
Interactions between CamKIIα and DAT’s   cytoplasmic 
C-  terminus are thought to bring about phosphorylation of nearby 
N-terminal tail serines to cause amphetamine-induced efflux.146 
It will be interesting to see if CamKIIα is similarly involved in 
estrogen-induced dopamine efflux.
Currently, we only know that DAT function is   differentially 
regulated by different physiological and non  physiological 
estrogens.58,148 Functional and structural homologies of the 
transporters suggest that similar estrogenic mechanisms could 
affect all transporters in this family (DAT, SERT, and NET). 
Estrogens are already implicated in control of SERT and NET 
function and related disease etiologies.47,104 So while it is now 
well recognized that these transporters can be regulated by 
acute and selective responses via kinases and phosphatases, 
and that estrogens can activate kinases and phosphatases,140,151 
it is unknown if estrogens will be one of the initial triggers of 
phosphoregulation of cellular neurotransmitter machineries, 
as has been shown for other targets.152,153
Xenoestrogens (nonphysiological 
estrogens) and their role  
in women’s mental health
Estrogenic toxins or environmental estrogens (see examples 
in Figure 3) are capable of mimicking the effects of endog-
enous estrogens, but usually not perfectly. Thus they can 
initiate more, less, different, and/or mistimed estrogenic 
actions that can lead to disruptions of estrogenic signal-
ing, as shown in several recent studies.151,154–159 Common 
human exposure levels have been associated with a variety 
of reproductive, neurological, and other impairments.160–163 
Bisphenol A (BPA), a monomer of polycarbonate plastics, 
is found in beverage bottles, canned food liners, and epoxy 
dental sealants.164–166 Nonylphenol (NP) and structurally 
related alkylphenols are surfactant manufacturing byproducts 
and also found in detergents, cleaning materials, and pesti-
cides.167 Diethylstilbestrol (DES) is a potent pharmaceutical 
estrogen that was prescribed to prevent miscarriages in the 
1950s to 1970s; unfortunately, although not really preventive 
for miscarriage, DES frequently caused multiple reproduc-
tive tract abnormalities in offspring, and cancers in some.168 
DDE, endosulfan, and dieldrin are estrogenic pesticides that 
have been associated with neurological impairments.169–172 
Besides manufacturing exposures, these compounds break 
down slowly, so persistent deposits are found in the soil and 
water, where plants and animals, and thus food supplies 
become exposed, subsequently passing these exposures on 
to humans and their infants.173,174 Because many of these 
xenoestrogenic compounds bioaccumulate in fat tissues, 
resulting in prolonged and escalating human exposures, 
the exposure levels causing deleterious health effects are 
actively debated. Other discrepancies between reports 
arise from the insensitivity of some animal models to the 
effects of xenoestrogens.175 However, toxicities to cellular 
signaling functions can occur at much lower concentrations 
than the maximum currently allowed by law.155,157,176–179 We 
also know that some pharmaceutical estrogens become 
environmental contaminants because of pervasive human 
use (eg, ethinylestradiol in birth control pills). The known 
behavioral effects of these compounds at environmentally 
relevant concentrations are still relatively few, due to lim-
ited data. However, BPA is now known to adversely affect 
some sociosexual behaviors,180–182 locomotion,183 spatial 
learning/memory,184 and fear/anxiety185,186 at relatively 
low doses.
Like E2, xenoestrogens can increase dopamine efflux 
by changing the amount or function of DAT in the cell 
  membrane.187 Xenoestrogens could further exacerbate the 
effects of physiological estrogens on transporters via these 
mechanisms, perhaps with behavioral consequences. In 
rodent models, prenatal and neonatal exposure to BPA leads 
to enhanced sensitivity to the rewarding effects of metham-
phetamine188 and morphine.189 It remains to be seen if there are 
associations between human xenoestrogen exposure during 
specific developmental stages and an increased vulnerability 
to drug addictions later in life, with possible gender differ-
ences. Developmental effects of xenoestrogen exposure have 
recently been shown in rodents in diseases of the immune 
system such as asthma179 and in cerebellar neurons.178
Phytoestrogens (derived from plant sources) are another 
type of nonphysiological or xenoestrogen. Many are   important 
constituents of Asian diets, which contain approximately 
10-fold higher concentrations of many   phytoestrogens than 
Western diets.190,191 Phytoestrogen-rich diets are thought to 
be one reason why women in cultures who eat them have 
less dramatic symptoms of menopause (such as hot flashes, 
osteoporosis, rise in heart disease), presumably due to the 
ability of phytoestrogens to replace some of the beneficial 
effects of estrogens.192 These cultures also have lower 
  incidences of estrogen exposure-related cancers,193 suggest-
ing that some phytoestrogens may oppose the carcinogenic 
effects of   physiological estrogens and some xenoestrogens. 
Finally, phytoestrogens may protect against brain damage and 
aging,194,195 although studies are still few and conflicting.196International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Unlike E2, which binds to both ER subtypes with   relatively 
equal affinity, some phytoestrogens bind with higher affinity 
to ERβ (measured on nuclear version of the receptors), and 
therefore could affect behaviors quite selectively if the   affinities 
for the membrane versions of ERβ are the same. Because 
  membrane receptors are in a different chemical environment 
(lipid) and therefore expected to assume alternate protein con-
formations, it is not surprising that they have different potencies 
for estrogenic effects initiated there, compared to transcriptional 
effects initiated in the nucleus. Phytoestrogens and many other 
xenoestrogens show a much higher potency in nongenomic 
responses, therefore we expect their binding affinities could 
be higher for mERs. It is probably not   correct to just “adopt” 
the literature on nuclear measurements of binding affinity to 
fit the membrane receptor. Though we would like to measure 
the binding affinities for membrane steroid receptors directly, 
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these data are very difficult to interpret because binding of a 
lipophilic ligand to a receptor lodged in a lipid membrane is 
subject to very high levels of nonspecific binding. However, if 
binding to the nuclear receptor has any relevance for predicting 
binding affinities for the membrane forms of the receptors, there 
are several examples which might predict higher activities via 
ERβ. For example, the plant estrogens coumestrol and several 
isoflavonoids bind more tightly to ERβ.190,197–199
Phytoestrogens have been implicated in memory and 
learning,196,200 and can have anxiolytic effects.200–202 Some 
phytoestrogenic compounds can also antagonize the effects 
of E2; for example, while coumestrol by itself does not affect 
locomotor activity, it can antagonize the effects of E2.203 
Besides its higher affinity for ERβ, coumestrol might act 
by triggering ERβ-mediated compensatory inhibition in the 
face of ERα activity in both genomic204,205 and nongenomic 
activation systems. The latter recent result demonstrated that 
estrogenic effects on the DAT (reversal of the transporter 
to cause efflux) are mainly mediated via ERα, but that an 
ERβ-selective synthetic ligand is inhibitory in the presence 
of ERα activity.103 Phytoestrogens can also act as agonists 
directly via ERβ in the brain206 and at the cellular level,103 in 
the absence of any ERα stimulation.
Estrogen replacement therapeutic 
strategies: pros and cons
It is very important to obtain low dose, wide dose, and 
  temporal response information about compounds that mimic 
estrogens, to determine if and when they are safe for use as 
therapeutics. Many previous researchers have examined the 
actions of only very high concentrations of nonphysiological 
estrogens, under the mistaken assumption that dose-response 
relationships are always monotonic and entirely   predictable, 
and that the effects of lower and noneffective doses 
could be extrapolated downwards. We now know that such 
  extrapolations are incorrect,207 and that estrogenic actions via 
nongenomic responses are nonmonotoic.157,178 We have also 
learned that the temporal phasing of estrogenic and xenoestro-
genic responses is different,177,208 suggesting that combinations 
of these compounds with one another might disrupt normal 
regulation by causing sustained responses, or cancelling each 
other out,148 rather than demonstrating the oscillating signals 
caused by endogenous estrogens. Thus the actions of multiple 
different estrogens and their pathways are complex.154,209 To 
understand the breadth of possible disease vulnerabilities 
influenced by variant   endogenous and exogenous hormone 
levels we need to establish the principles of individual and 
combinatorial action of   estrogenic   compounds for each brain 
region, tissue type, and   developmental stage.
To treat diseases associated with loss or imbalance 
of physiological estrogens (due to menopause, surgery, 
  pregnancy, parturition, or cycle disturbances), or perhaps 
to counteract the effects of harmful nonphysiological 
estrogens, it is important to design estrogen replacement 
or augmentation strategies that deliver the most effective 
estrogens, over the lowest possible effective doses, with the 
most effective scheduling and fewest side effects.   Currently, 
E2 and equine urine estrogen mixtures (Premarin®) are the 
most frequently used replacement therapies. While there are 
numerous   suggestions in the clinical literature that replacing 
lost   estrogens can be beneficial (to bones and skin, in specific 
cognitive and mood states, and perhaps for the   cardiovascular 
system), there are also risks involved. Long term use of 
replacement estrogens can increase the risk of some   cancers, 
notably those of the breast and uterus,210 complicate 
  diagnostic procedures such as breast imaging,211 or   exacerbate 
some cardiovascular problems.32 Though some studies 
have linked replacement estrogens to a decline in specific 
  cognitive functions and increased heart disease,212–215 or have 
concluded that estrogens do not help prevent disease,216,217 
these effects may also depend upon the dose, the use of the 
most   appropriate estrogen metabolites, how long estrogen 
withdrawal occurred before replacement,218–220 or whether 
progestins are coadministered.221 Most of these parameters 
have yet to be systematically studied and agreed upon.
Protective effects of some estrogens against ischemic, 
glucocorticoid-induced, or other induced brain injury have 
been touted;222–224 however, such studies have been focused 
on very high doses of estrogens that, while acceptable for 
acute therapies to prevent death, are unacceptable for chronic 
therapeutic use because of the cancer risk. Therefore, we 
clearly do not yet understand how different estrogens and 
their metabolites at various doses and schedules may interact, 
especially given the nonmonotonic dose-response patterns that 
are becoming recognized as typical of nongenomic   steroid 
actions.225 It is thus critical to know the lowest   effective dose 
ranges of specific estrogens that regulate given functions 
such as neurotransmitter transporter and receptor activity. 
It remains to be proven conclusively if some   phytoestrogens 
or E2 metabolites could act therapeutically to either restore 
estrogenic effects on transporters when   endogenous estrogens 
are absent (such as to control hot flashes), or to act preventa-
tively as inhibitory estrogens in scenarios where estrogenic 
overstimulation results in cancers.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Summary
There are important differences between males and females 
in a number of functional responses and vulnerabilities to 
behavioral disorders. Signaling mechanisms, both genomic 
and nongenomic, operating via several different ER   proteins 
residing in different subcellular compartments, are   beginning to 
be found responsible for diverse actions of estrogens involved 
in these functions. Complex signaling cascades and receptor 
systems can be influenced by multiple   physiological estrogens, 
as well as some nonphysiological (dietary, pharmaceutical) 
and contaminant (environmental) estrogens. Such influences 
could have profound effects on the functioning of the brain 
and nervous system. Elucidating the underlying cellular 
  mechanisms via which variant estrogens and their   receptors act 
will provide explanations of how we might   intervene medically 
to address severely imbalanced estrogens that cause disease, or 
enlighten our choices among commercial products or foods/
dietary supplements that contain estrogens. These consid-
erations should also inform future decisions about hormone 
  replacements, analogs, and antagonists that could alleviate 
life stage-specific effects of estrogens or their withdrawal. 
An enhanced focus on the   relatively new area of nongenomic 
estrogenic effects may allow entirely new understandings and 
approaches to   treatment of these maladies, and perhaps change 
current   treatment standards. One such change could be the 
  preservation of ovaries in women undergoing hysterectomies, 
potentially justified because of the multiple beneficial estrogens 
that they provide.18   Hopefully, among these new understandings 
and opportunities will be ones that improve the diagnosis and 
treatment of mental state diseases for women.
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